Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Triptorelin - Debiopharm

Drug Profile

Triptorelin - Debiopharm

Alternative Names: ARVEKAP; AY 25650; BIM 21003; BN 52014; CL 118532; Debio 8200; Debio 8206; Debio 8206 CPP; Debio 8206 SC; Decapeptyl; Decapeptyl SR; Diphereline; Moapar; Pamorelin; Pamorelin LA; Salvacyl; Trelstar; Trelstar Depot; Triptodur; Triptorelin acetate; Triptorelin embonate; Triptorelin pamoate; Triptoreline; Tryptorelin; WY 42422

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tulane University
  • Developer Allergan; Arbor Pharmaceuticals; Debiopharm; European Organisation for Research and Treatment of Cancer; Ipsen; Orient Europharma; Pfizer; United Laboratories
  • Class Antineoplastics; Antivirals; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precocious puberty
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Endometriosis; Female infertility; Paraphilias; Precocious puberty; Prostate cancer; Uterine leiomyoma
  • Phase II Salivary gland cancer
  • Phase I Malignant melanoma

Most Recent Events

  • 17 Sep 2018 Phase-III clinical trials in Prostate cancer in China (IM, Controlled release, Six-month) (Ipsen pipeline, September 2018)
  • 15 Jun 2018 Phase-III clinical trials in Precocious puberty in China (IM) (Ipsen pipeline, June 2018)
  • 08 May 2018 Phase-I clinical trials in Malignant melanoma (Combination therapy, Late-stage disease) (unspecified) (Debiopharm pipeline, May 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top